PRINCIPI, MARIABEATRICE
 Distribuzione geografica
Continente #
NA - Nord America 7.689
EU - Europa 1.289
AS - Asia 779
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 6
SA - Sud America 6
AF - Africa 4
Totale 9.779
Nazione #
US - Stati Uniti d'America 7.675
CN - Cina 506
SE - Svezia 430
IT - Italia 236
DE - Germania 199
SG - Singapore 199
GB - Regno Unito 99
FI - Finlandia 93
UA - Ucraina 63
BE - Belgio 48
FR - Francia 39
VN - Vietnam 27
IN - India 17
RU - Federazione Russa 17
RO - Romania 16
IE - Irlanda 15
GT - Guatemala 9
ES - Italia 8
NL - Olanda 8
AU - Australia 6
BR - Brasile 5
EU - Europa 5
HK - Hong Kong 5
KR - Corea 5
CA - Canada 4
CZ - Repubblica Ceca 3
JP - Giappone 3
MK - Macedonia 3
AL - Albania 2
CH - Svizzera 2
HU - Ungheria 2
ID - Indonesia 2
PK - Pakistan 2
TW - Taiwan 2
ZA - Sudafrica 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AR - Argentina 1
BD - Bangladesh 1
BG - Bulgaria 1
BY - Bielorussia 1
DZ - Algeria 1
EE - Estonia 1
EG - Egitto 1
GE - Georgia 1
IL - Israele 1
IR - Iran 1
JM - Giamaica 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
MY - Malesia 1
NO - Norvegia 1
PL - Polonia 1
SA - Arabia Saudita 1
SM - San Marino 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
Totale 9.779
Città #
Fairfield 1.278
Woodbridge 916
Chandler 689
Houston 589
Ashburn 548
Seattle 499
Cambridge 464
Wilmington 421
Ann Arbor 416
Nyköping 366
Jacksonville 214
Singapore 145
Lawrence 133
Roxbury 129
Beijing 123
Nanjing 123
New York 113
Des Moines 77
Princeton 71
Bari 70
Inglewood 67
Dearborn 52
Brussels 47
San Diego 46
Boardman 45
Brooklyn 36
Dong Ket 26
Jiaxing 26
Shenyang 26
Hebei 24
Nanchang 24
Santa Clara 24
Tianjin 24
Los Angeles 19
Paris 19
Changsha 17
Dublin 15
Munich 14
London 13
Redwood City 13
Helsinki 12
Falls Church 11
Guangzhou 11
Pune 11
Rome 10
Guatemala City 9
Hefei 9
Jinan 9
Zhengzhou 9
Hangzhou 7
Kunming 7
Milan 7
Shanghai 7
Chicago 5
Hounslow 5
Kilburn 5
Mountain View 5
Norwalk 5
Orihuela Costa 5
San Jose 5
Washington 5
Wuhan 5
Edinburgh 4
Esslingen am Neckar 4
Hong Kong 4
Ningbo 4
Toronto 4
Triggiano 4
Bitetto 3
Böblingen 3
Florence 3
Frankfurt am Main 3
Indiana 3
Leawood 3
Madrid 3
San Francisco 3
San Mateo 3
Sterling 3
Taizhou 3
Tappahannock 3
Tetovo 3
Auburn Hills 2
Augusta 2
Brescia 2
Brno 2
Calimera 2
Castellammare Di Stabia 2
Catania 2
Colle Brianza 2
Foggia 2
Frattamaggiore 2
Groningen 2
Karachi 2
Lecce 2
Louisville 2
Melbourne 2
Monopoli 2
Mumbai 2
Preganziol 2
Prescot 2
Totale 8.226
Nome #
Assessment of Disease Activity in Small Bowel Crohn’s Disease: Comparison between Endoscopy and Magnetic Resonance Enterography Using MRIA and Modified MRIA Score 141
Gastrointestinal bleeding from vascular malformations: Is octreotide effective to rescue difficult-to-treat patients? 129
Small intestinal bacterial overgrowth and celiac disease: A systematic review with pooled-data analysis 125
Systematic review with meta-analysis: post-operative complications and mortality risk in liver transplant candidates with obesity. 123
May the assessment of baseline mucosal molecular pattern predict the development of gluten related disorders among microscopic enteritis? 121
Differences in dietary habits between patients with inflammatory bowel disease in clinical remission and a healthy population 121
Effect of probiotic or prebiotic supplementation on antibiotic therapy in the small intestinal bacterial overgrowth: a comparative evaluation 115
Clinical relevance of serum non-organ-specific antibodies in patients with HCV infection receiving direct-acting antiviral therapy 115
Chromoendoscopy for Surveillance in Ulcerative Colitis and Crohn's Disease: A Systematic Review of Randomized Trials 113
Extra-intestinal manifestations of non-celiac gluten sensitivity: An expanding paradigm 112
Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Disease: Prevalence and Risk Factors 111
Systematic review with network meta-analysis: endoscopic techniques for dysplasia surveillance in inflammatory bowel disease 109
Endothelial function and cardiovascular risk in active inflammatory bowel diseases. 107
Evolution of nonspecific duodenal lymphocytosis over 2 years of follow-up 105
Oral Tacrolimus (FK-506) in Crohn' s disease complicated by fistulae of perineum 102
null 101
null 100
null 99
A mysterious case of gastroparesis: could the secret be found in a drink? 98
Tailored therapy guided by multichannel intraluminal impedance pH monitoring for refractory non-erosive reflux disease 98
Dietary Lifestyle and Colorectal Cancer Onset, Recurrence, and Survival: Myth or Reality? 96
Chemoprevention of inflammation-related colorectal cancer by silymarin-, acetyl-11-keto-beta-boswellic acid-, curcumin- and maltodextrin-enriched dietetic formulation in animal model 96
Stool Investigations for Colorectal Cancer Screening: From Occult Blood Test to DNA Analysis 95
Estrogens, phytoestrogens and colorectal neoproliferative lesions 94
null 93
Pattern of apoptosis in Crohn’s disease: a singular aspect? 91
null 89
Long-term safety of in utero exposure to anti-TNFα drugs for the treatment of inflammatory bowel disease: Results from the multicenter European TEDDY study 89
Altered molecular pattern of mucosal healing in Crohn's disease fibrotic stenosis 88
null 88
Phytoestrogens/insoluble fibers and colonic estrogen receptor β: Randomized, double-blind, placebo-controlled study 88
null 86
null 86
The PROSit cohort of infliximab biosimilar in IBD: A prolonged follow-up on the effectiveness and safety across Italy 85
Mesalazine for people with diverticular disease: A systematic review of randomized controlled trials 85
Intestinal microbiota: The explosive mixture at the origin of inflammatory bowel disease? 83
null 83
Olmesartan Associated Enteropathy: Usefulness of Video Capsule Endoscopy in a Case With Doubtful Upper Endoscopic/Histological Picture 83
Systematic review: Renin-angiotensin system inhibitors in chemoprevention of hepatocellular carcinoma 82
null 81
null 81
null 80
null 80
Red flags for appropriate referral to the gastroenterologist and the rheumatologist of patients with inflammatory bowel disease and spondyloarthritis 80
null 79
null 79
null 79
Influence of chemotherapy on total energy expenditure in patients with gastrointestinal cancer: A pilot study 78
Alimentary disorders in young females with irritable bowel syndrome or ulcerative procto-sigmoiditis: A preliminary report. 77
null 77
The association between cardiac and gastrointestinal disorders: causal or casual link? 76
Liver fibrosis in primary intestinal lymphangiectasia: an undervalued topic 75
Lymphocytic duodenitis or microscopic enteritis and gluten-related conditions: What needs to be explored? 74
Optimizing proton pump inhibitors in Helicobacter pylori treatment: Old and new tricks to improve effectiveness 74
null 74
null 73
null 73
null 72
Predictivity of Autoimmune Stigmata for Gluten Sensitivity in Subjects with Microscopic Enteritis: A Retrospective Study 72
null 71
null 70
null 70
null 70
null 69
Non steroidal anti-inflammatory drug induced damage on lower gastro-intestinal tract: is there an involvement of microbiota? 69
null 69
null 68
null 67
Fibrogenesis and fibrosis in inflammatory bowel diseases: Good and bad side of same coin? 67
Low Molecular Weight Heparin in Portal Vein Thrombosis of Cirrhotic Patients: Only Therapeutic Purposes? 65
null 65
Infliximab therapy downregulation of basic fibroblast growth factor/syndecan 1 link: a possible molecular pathway of mucosal healing in ulcerative colitis. 64
Anti-tumor necrosis factor treatment in occult hepatitis B virus infection: a retrospective analysis of 62 patients with psoriatic disease 63
Probiotics and Helicobacter pylori 63
Celiac disease and common variable immunodeficiency: a familial inheritance? 63
null 63
Inter-observer agreement of a new endoscopic score for ulcerative colitis activity: Preliminary experience 63
null 62
Chronic viral hepatitis in a cohort of inflammatory bowel disease patients from southern Italy: A case-control study 62
Mucosal expression of Basic Fibroblastic Growth Factor, Syndecan 1 and tumour necrosis factor-α in Crohn's disease in deep remission under treatment with anti-TNFα antibodies 61
Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) 61
La gastrite cronica da Helicobacter Heilmannii: una nuova entità istopatologica. L’ infezione da Helicobacter pilori: aggiornamento continuo G Bianchi Porro, G Maconi, F Parente 60
null 59
null 59
null 59
Immunosuppressant supplementation to infliximab in Crohn's disease with extraintestinal involvement: A benefit in the long term? 59
Prevalence and associated factors of obesity in inflammatory bowel disease: A case-control study 59
null 58
null 57
Long-term tacrolimus: a promising therapeutic approach for Crohn’s disease 57
The Italian Registry of Therapeutic Apheresis: granulocyte-monocyte apheresis in the treatment of inflammatory bowel disease. A multicentric study 56
null 55
null 55
Role of concomitant therapy for Helicobacter pylori eradication: A technical note 54
Lupus nephritis improvement after anti-tumor necrosis factor alpha monoclonal antibody (infliximab) treatment for Crohn disease: a case report 53
Seronegative celiac disease: where is the specific setting? 53
Lactobacillus reuteri strain combination in helicobacter pylori infection: A randomized, double-blind, placebo-controlled study 52
Effect of Helicobacter Pylori eradication on gastric epithelial proliferation. Relationship with ras oncogene p21 expression 52
Helicobacter pylori primary and secondary genotypic resistance to clarithromycin and levofloxacin detection in stools: A 4-year scenario in Southern Italy 52
null 51
Totale 7.964
Categoria #
all - tutte 44.354
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 44.354


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.111 0 0 0 0 319 210 284 346 404 202 228 118
2020/20211.736 116 174 98 137 236 111 139 211 91 225 83 115
2021/20221.020 101 43 37 37 53 99 27 54 61 89 164 255
2022/20231.708 242 238 126 143 156 242 24 186 262 12 48 29
2023/2024571 36 107 23 55 53 164 14 23 6 27 13 50
2024/2025370 40 36 162 78 54 0 0 0 0 0 0 0
Totale 10.332